Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer.

Halpern NaamaBen BoursiEinat Shacham-ShmueliEinav Nili Gal-YamOfer MargalitTalia GolanTamar BellerGal StraussDafna YahavEyal Leshem

Published in: Oncology and therapy (2023)

In a cohort of vaccinated patients with breast cancer who received systemic anti-neoplastic treatment 7-14 days after SARS-CoV-2 infection, we did not observe substantially higher rates of ED visits, hospitalizations, or deaths compared with a similar cohort of pre-COVID-19 patients with breast cancer. Most patients received the next planned cycle on time. Early resumption of systemic anti-neoplastic treatment following SARS-CoV-2 infection in vaccinated patients with breast cancer with a negative antigen test at the day of treatment appeared to be safe. Additional data on larger cohorts and other malignancies are needed to support clinical guidelines.

Keyphrases

emergency department
sars cov
end stage renal disease
chronic kidney disease
machine learning
ejection fraction
respiratory syndrome coronavirus
combination therapy
big data
replacement therapy
deep learning